SecBot SecBot
144 ·Filed Nov 3, 2026

TWST

Twist Bioscience Corp
NEUTRAL
Impact 2/10
Horizondays Processed13d 6h ago SEC0001959173-26-007692
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

This is a tax-motivated sale of a small equity vesting tranche, not a change in the CEO's outlook. The filing is routine and does not alter the insider selling pattern. Monitor the next Form 4 for actual execution and any larger open-market sales.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$140.30
T+0 close · Nov 3, 2026 · via day close
Latest settled
−5.82%
T+5 · $132.13
Vs SPY
−5.24%
α at T+5
Next horizon
T+20
in 15d
  1. T+0 · Nov 3 $140.30entry
  2. T+1 · 13d ago +1.63%α −0.03% · $142.58
  3. T+5 · 7d ago −5.82%α −5.24% · $132.13
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Emily M. Leproust filed a Form 144 to sell 4,573 shares of Twist Bioscience common stock, valued at approximately $619,192. The shares were acquired via restricted stock vesting on November 2, 2026, and the sale is intended to cover a tax obligation from the settlement of a vested equity award. This is a routine, small disposition relative to her prior large sales and the company's $11.5B market cap.

Key Facts

  • CEO Emily M. Leproust filed Form 144 to sell 4,573 shares of common stock.
  • Estimated proceeds of ~$619,192 based on a price of ~$135.40 per share.
  • Shares were acquired on November 2, 2026 via restricted stock vesting.
  • Sale is to cover a tax obligation from the settlement of a vested equity award.
  • Leproust has sold over 600,000 shares in the prior three months (Aug-Oct 2026) for aggregate proceeds exceeding $90M.
  • The 4,573 shares represent less than 1% of her recent trading volume and a negligible fraction of the company's 11.5B market cap.

Financial Impact

~$619,192 in proceeds from 4,573 shares sold for tax withholding purposes.

dilutioninsider ownership

Risk Factors

  • CEO has been a consistent large seller over the past three months, which could weigh on sentiment if the pattern continues.
  • Form 144 is an intent to sell; the actual sale may not occur or may be at a different price.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
74% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-007692
Document: 0001959173-26-007692-index.html0001959173-26-007692
Document: 0001959173-26-007692.txt0001959173-26-007692

US Market Status

Market Closed · Opens Wed (11h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026